Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation Study of AP-002 In Patients With Advanced or Recurrent Solid Tumors

NCT04143789 is registered in ClinicalTrials.gov with Altum Pharmaceuticals INC as lead sponsor.

NCT NCT04143789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04143789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation Study of AP-002 In Patients With Advanced or Recurrent Solid Tumors
Lead sponsor
Altum Pharmaceuticals INC
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 27, 2019
Completion date
April 30, 2021
Enrollment
61 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor